
This pooled analysis of phase III studies on subcutaneous (SC) tanezumab for moderate to severe hip or knee osteoarthritis (OA) assessed joint safety events, including rapidly progressive osteoarthritis (RPOA). Adjudicated outcomes showed a dose-dependent risk of composite joint safety events, RPOA, and total joint replacement with tanezumab compared to nonsteroidal anti-inflammatory drug (NSAID) and placebo. Associations were found between RPOA and more severe radiographic/symptomatic OA, with higher risks observed in patients with baseline Kellgren-Lawrence grade 2 or 3 OA and KL grade 4 joints.
Like
Save
Share